Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Fusion Antibodies secures contract exceeding £85,000 with major US pharmaceutical client for antibody development.
Oct 22, 2026
Contract Type
contract
Belfast City DistrictBiotechnology
Description
Fusion Antibodies has landed a contract worth over £85,000 with a major US drugmaker under an existing master services agreement. The project involves transient gene expression and CryoEM analysis, contributing to the client’s therapeutic antibody development program.
Company Information
Company
Fusion Antibodies plc
Location
Belfast City District, Northern Ireland, United Kingdom
About
Fusion Antibodies plc is a Belfast-based company specializing in antibody discovery and engineering. It supports pharmaceutical companies in developing therapeutic antibodies. The company is publicly traded on the AIM market under the ticker FAB. It aims to strengthen commercial relationships and expand its customer base among established pharmaceutical groups.
Predictive Intelligence
Strategic
ML-powered predictions for Fusion Antibodies plc's next move